Trifluridine + Tipiracil interactions
Checked as Trifluridine + Tipiracil in this data source.
Full monograph for Trifluridine + TipiracilCheck it against another medicine
Medicines
78 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumabvia Trifluridine | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…2 documented mechanisms | 12 sources — open the full entry |
| Baricitinibvia Trifluridine | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.2 documented mechanisms | 7 sources — open the full entry |
| Clozapinevia Tipiracil, Trifluridine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.3 documented mechanisms | 13 sources — open the full entry |
| Deferipronevia Trifluridine | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.2 documented mechanisms | 9 sources — open the full entry |
| Etanerceptvia Trifluridine | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…2 documented mechanisms | 12 sources — open the full entry |
| Golimumabvia Trifluridine | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of…2 documented mechanisms | 12 sources — open the full entry |
| Infliximabvia Trifluridine | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections…2 documented mechanisms | 12 sources — open the full entry |
| Leflunomidevia Trifluridine | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to…2 documented mechanisms | 4 sources — open the full entry |
| Rotavirus Vaccinevia Trifluridine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Tofacitinibvia Trifluridine | Major | Others · Synergy | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.2 documented mechanisms | 2 sources — open the full entry |
| Upadacitinibvia Trifluridine | Major | Others · Synergy | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.2 documented mechanisms | 2 sources — open the full entry |
| Yellow Fever Vaccinevia Trifluridine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Azathioprinevia Trifluridine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections…2 documented mechanisms | 5 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocainevia Tipiracil, Trifluridine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…3 documented mechanisms | 15 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin Evia Trifluridine | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses…2 documented mechanisms | 18 sources — open the full entry |
| Brigatinibvia Tipiracil | Moderate | Excretion | Coadministration with brigatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)…2 documented mechanisms | 6 sources — open the full entry |
| Capmatinib Hydrochloridevia Tipiracil | Moderate | Excretion · Metabolism | Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of multidrug and toxin…2 documented mechanisms | 3 sources — open the full entry |
| Chloramphenicol (Ophthalmic)via Tipiracil, Trifluridine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…3 documented mechanisms | 15 sources — open the full entry |
| Chloramphenicol (Oral)via Tipiracil, Trifluridine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…3 documented mechanisms | 15 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloridevia Tipiracil, Trifluridine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…3 documented mechanisms | 15 sources — open the full entry |
| Crizotinibvia Tipiracil | Moderate | Metabolism | Coadministration with crizotinib may theoretically increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450…2 documented mechanisms | 8 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiolvia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Denosumabvia Trifluridine | Moderate | Synergy | Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections.2 documented mechanisms | 3 sources — open the full entry |
| Dexamethasone + Chloramphenicolvia Tipiracil, Trifluridine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of…3 documented mechanisms | 15 sources — open the full entry |
| Dienogest + Estradiol Valeratevia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio + HIBvia Trifluridine | Moderate | Antagonism · Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a…2 documented mechanisms | 21 sources — open the full entry |
| Diroximel Fumaratevia Trifluridine | Moderate | Synergy | The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may…2 documented mechanisms | 8 sources — open the full entry |
| Drospirenonevia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Drospirenone + Estetrolvia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Drospirenone + Estradiolvia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…4 documented mechanisms | 37 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mgvia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…4 documented mechanisms | 37 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolatevia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…4 documented mechanisms | 37 sources — open the full entry |
| Erdafitinibvia Tipiracil | Moderate | Excretion | Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2), resulting in…2 documented mechanisms | 5 sources — open the full entry |
| Estradiolbasevaginal creamvia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Estradiol + Dydrogesteronevia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Estradiol Hemihydrate + Progesterone Micronizedvia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Estradiol Valeratevia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Ethinyl Estradiol + Desogestrel0.02 mg0.03 mgvia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Ethinyl Estradiol + Gestodenevia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumaratevia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…4 documented mechanisms | 37 sources — open the full entry |
| Ethinyl Estradiol + Lynestrenol0.0375 mg0.05 mgvia Tipiracil | Moderate | Antagonism · Others | RECOMMENDED: Coadministration with tipiracil-trifluridine may reduce the efficacy of contraceptive hormones. The mechanism has not been established…2 documented mechanisms | 37 sources — open the full entry |
| Filgrastimvia Trifluridine | Moderate | Antagonism · Others | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given…2 documented mechanisms | 8 sources — open the full entry |
| Ganciclovirvia Trifluridine | Moderate | Synergy | The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or…2 documented mechanisms | 11 sources — open the full entry |
| Hepatitis B Vaccine [rDNA]via Trifluridine | Moderate | Antagonism · Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a…2 documented mechanisms | 21 sources — open the full entry |
| Inactivated Hepatitis A vaccinevia Trifluridine | Moderate | Antagonism · Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a…2 documented mechanisms | 21 sources — open the full entry |
| Ketoconazolevia Tipiracil | Moderate | Excretion · Metabolism · Others | Coadministration with inhibitors of the organic cation 2 (OCT2) or multidrug and toxin extrusion 1 (MATE1) transporters may theoretically increase the plasma…2 documented mechanisms | 16 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleoveravia Tipiracil | Moderate | Excretion · Metabolism · Others | Coadministration with inhibitors of the organic cation 2 (OCT2) or multidrug and toxin extrusion 1 (MATE1) transporters may theoretically increase the plasma…2 documented mechanisms | 16 sources — open the full entry |
| Lactobacillus Rhamnosus GGvia Trifluridine | Moderate | Others | Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms… | 11 sources — open the full entry |
| Lamivudine + Zidovudinevia Trifluridine | Moderate | Antagonism | Coadministration with trifluridine may decrease the therapeutic effects of drugs that are substrates of thymidine kinase, such as zidovudine. The proposed…2 documented mechanisms | 7 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapinevia Trifluridine | Moderate | Antagonism | Coadministration with trifluridine may decrease the therapeutic effects of drugs that are substrates of thymidine kinase, such as zidovudine. The proposed…2 documented mechanisms | 7 sources — open the full entry |
This source documents no food, condition or duplication entries for Trifluridine + Tipiracil.